Industry Insights: Behind the Scenes of BPS Bioscience Custom R&D
Explore how BPS Bioscience utilizes a scientist-driven, milestone-measured framework to de-risk custom R&D and screening projects for biopharma teams.
Industry Insights with Henry Zhu and BPS Bioscience
Henry Zhu, CEO of BPS Bioscience, reflects on 20 years of growth, innovation, and the company’s role in advancing drug discovery research.
Understanding Biological Material Licensing for Preclinical Research
Learn why biological material licensing matters in preclinical research, what risks to avoid, and how to manage licenses for cell lines, organoids, PDX models, and more.
Featured Webinars
From Clinical Data to Actionable Assets for Pharmaceutical R&D
Tuesday, June 16, 2026
Sponsor: France Tissue Bank
Partner: Scientist.com
Screening the Unscreenable: Expanding the Reach of Drug Discovery
Thursday, June 4, 2026
Sponsor: SandboxAQ
Advertisement
